Press Release
RainDance Technologies Announces Formation of French Subsidiary
LEXINGTON, MASSACHUSETTS, July 10, 2008 — RainDance Technologies, Inc., a provider of innovative droplet-based solutions for human health and disease research, today announced the formation of RainDance Technologies France SARL, a wholly owned subsidiary focused on securing research partnerships in Europe. Based in Strasbourg, RainDance Technologies France SARL will begin operations by September 1, 2008.
“The creation of RainDance Technologies France SARL enhances our company’s ability to collaborate with leading European institutions engaged in drug discovery, genomics, and molecular biology research,” said Chris McNary, President and Chief Executive Officer, RainDance Technologies. “In addition, it will position our proven droplet-based technology for new business opportunities as we expand our presence in the growing European market. RainDance Technologies’ speed and simplicity will enable biomedical researchers to design experiments in ways that were previously unaffordable or unthinkable.”
To house its new subsidiary, RainDance has leased facilities at the Institut de Science et d'Ingénierie Supramoléculaires (ISIS), Université Louis Pasteur, in Strasbourg.
“Locating our offices at ISIS will continue our close relationship with Dr. Andrew Griffiths, a RainDance founder and the Director of the ISIS Chemical Biology Laboratory,” said McNary. “Dr. Griffiths is renowned for his work in the development of phage display for the selection of human antibodies for therapy, and for the development of a novel technique for selection and directed evolution of both nucleic acids and proteins. His support and guidance will be significant assets as we identify and engage in new research partnerships,” he said.
About RainDance Technologies, Inc.
RainDance's proprietary technology platform delivers exquisite sensitivity and data quality that inspires scientists, researchers and clinicians to rethink the way they design experiments, approach discovery, or conduct clinical diagnostics. The core RainStorm™ technology empowers customers to conduct de novo science in an ultra-high throughput, simple, flexible, and low-cost manner. RainDance's commercial products include instruments and high-value consumables and reagents for sequence enrichment for next-generation sequencing, ultra-deep sequencing, and methylation analysis. RainDance sells directly in the U.S. and in Europe, and is building distribution networks in Europe and Asia-Pacific. RainDance Technologies has approximately 70 employees worldwide. For more information, please visit www.raindancetech.com.
RainStorm is a trademark of RainDance Technologies, Inc.
For corporate questions contact:
Chris McNary
RainDance Technologies
44 Hartwell Avenue
Lexington, MA 02421
Phone — 781-861-6300
mcnaryc@raindancetech.com
For technical questions contact:
James Brayer
RainDance Technologies
44 Hartwell Avenue
Lexington, MA 02421
Phone — 781-861-6300
info@raindancetech.com
For press inquiries:
Colin Sanford
Phone — 203-340-2441
colin@bioscribe.com
